BioSpace News Archive

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration denied the Breakthrough Therapy designation request for ZYESAMI® and emphasized its focus on the company’s NRX-101 BTD compound for Bipolar Depression associated with Suicidality.

Wilmington, Delaware, United States: According to the report, the global medical waste management market was valued at US$ 15.3 Bn in 2020 and is projected to expand at a CAGR of 6.2% from 2021 to 2028.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer and other serious diseases, will present preclinical data from studies of the company’s two novel investigational spleen tyrosine kinase inhibitors, entospletinib and lanraplenib.

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. announced that data from the zandelisib clinical development program, including the Phase 2 TIDAL study evaluating the intermittent dosing of zandelisib, an orally administered investigational phosphatidylinositol 3-kinase delta inhibitor in clinical development for the treatment of B-cell malignancies, is highlighted in a poster and an oral discussion session at the European Hematology Association 2022 Hybrid Congress.

AbbVie announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with ruxolitinib in JAK inhibitor naïve patients with myelofibrosis, a rare and difficult to treat blood cancer.

ADC Therapeutics SA announced results from the ongoing pivotal Phase 2 clinical trial of camidanlumab tesirine in relapsed or refractory Hodgkin lymphoma.

Bavarian Nordic A/S announced that the U.S. Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 500,000 doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox, for delivery in 2022.

ChromaDex Corp. a global bioscience company dedicated to healthy aging, announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into mainland China.

Fulcrum Therapeutics, Inc® (Nasdaq:FULC), a clinical stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced clinical proof-of-concept data from the ongoing Phase 1b trial of FTX-6058 for the treatment of sickle cell disease (SCD).

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. ( Hayward, California , U.S.) (RefleXion) today announced the signing of a co-development and commercialisation agreement, to expand the use of Telix’s prostate cancer imaging agent, Illuccix ®.